Literature DB >> 34074486

How to Select the Optimal Candidates for Renal Mass Biopsy.

Alberto Martini1, Alessandro Larcher2, Carlo Andrea Bravi2, Paolo Capogrosso2, Ugo Giovanni Falagario3, Giuseppe Fallara2, Francesco Pellegrino2, Fabio Muttin2, Chiara Re2, Alberto Briganti2, Andrea Salonia2, Roberto Bertini2, Francesco Montorsi2, Umberto Capitanio2.   

Abstract

Surgical treatment of small renal masses (RMs) is still characterized by a non-negligible rate of benign histology, ultimately resulting in overtreatment. Since the risk of kidney cancer increases with age and the risk of malignancy usually increases with tumor size, we created a model based on patient age, RM size, and their interaction for predicting malignant histology. As male sex is associated with a higher risk of renal malignancy, we also stratified our analyses by sex. We used data for 2252 patients with cT1N0M0 disease (1551 male [69%], 701 female [31%]). On logistic regression, both age and RM size were predictors of malignant histology. For males, the odds ratio (OR) was 1.82 (95% confidence interval [CI] 1.78-2.80) for age and 2.04 (95% CI 1.69-2.47) for RM size; for females, the OR was 1.82 (95% CI 1.78-2.80) for age and 2.04 (95% CI 1.69-2.47) for RM size (all p ≤ 0.007), with a significant continuous-by-continuous interaction between them (p < 0.001) in both models. On decision curve analysis, the model demonstrated clinical utility for predicting malignancy at a probability of <55% for males and <60% for females. Individuals with lower probability should be considered for renal biopsy and those with higher probability for upfront surgery. The model was also more informative than RM size alone in predicting malignancy, which currently represents the only absolute criterion for active surveillance eligibility. PATIENT
SUMMARY: In this study we analyzed the correlation between age and tumor size for predicting tumor malignancy. The aim in management is to balance the utility of performing a biopsy and the appropriateness of upfront surgery against the ultimate goal of decreasing overtreatment.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active surveillance; Kidney cancer; Renal biopsy; Renal cancer; Small renal mass

Mesh:

Year:  2020        PMID: 34074486     DOI: 10.1016/j.euo.2020.10.001

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  3 in total

1.  Pre-operative Serum Albumin as a Potential Predictor of Benign Lesions in Renal Masses.

Authors:  Sho Sekito; Yuji Ogura; Norihito Soga; Takahiro Kojima
Journal:  Cancer Diagn Progn       Date:  2022-05-03

2.  Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.

Authors:  Xiaoting Wei; Jianmin Xu; Shuyuan Zhong; Jinsen Zou; Zhiqiang Cheng; Zhiguang Ding; Xuhui Zhou
Journal:  Abdom Radiol (NY)       Date:  2022-07-05

3.  Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET/CT in patients with primary prostate cancer.

Authors:  Zhilong Yi; Siqi Hu; Xiaofeng Lin; Qiong Zou; MinHong Zou; Zhanlei Zhang; Lei Xu; Ningyi Jiang; Yong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-11-30       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.